Når man ser på de patienter, der fik deres første behandling for metastatisk brystkræft, var der ingen forskel mellem lægemidlerne, for så vidt angår den målte virkning (f. eks. tid til sygdomsprogression og overlevelse).
When looking only at the patients who were receiving their first treatment for metastatic breast cancer, there was no difference between the medicines in terms of measures of effectiveness such as the time until the disease got worse and survival.